The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Open accessAbstract
Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by both terminal keratinocyte differentiation defects and strong type 2 immune responses. In contrast to chronic plaque-type psoriasis, AD is now understood to be a much more heterogeneous disease, with additional activation of Th22, Th17/IL-23 and Th1 cytokine pathways, depending on the subtype of the disease. In this review, we discuss our current understanding of the AD immune map in both early-onset as well as chronic disease. Clinical studies using broad and targeted therapeutics have helped to elucidate the contribution of various immune axes to the disease phenotype. Importantly, immune activation extends well beyond lesional AD, as non-lesional skin and the blood component harbor AD-specific inflammatory changes. For this reason, future therapeutics will need to focus on a systemic treatment approach, especially in patients suffering from moderate-to-severe disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Self-citationAtopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,055
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationSecukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960
Self-citationPlasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationFilaggrin Mutations Associated with Skin and Allergic Diseases
Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011040 · Cited by 1,217
Self-citationCytokine modulation of atopic dermatitis filaggrin skin expression
Howell, M. D., Kim, B. E., Gao, P., Grant, A. V., Boguniewicz, M., DeBenedetto, A., Schneider, L., Beck, L. A., Barnes, K. C., & Leung, D. Y. M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.031 · Cited by 1,084
Self-citation
Cited by
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationAtopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman-Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 631
Self-citationDe Pessemier, B., Grine, L., Debaere, M., Maes, A., Paetzold, B., & Callewaert, C. (2021) · Microorganisms · doi:10.3390/microorganisms9020353 · Cited by 628
Molecular Mechanisms of Atopic Dermatitis Pathogenesis
Sroka-Tomaszewska, J., & Trzeciak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084130 · Cited by 577
Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship
Geoghegan, J. A., Irvine, A. D., & Foster, T. J. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2017.11.008 · Cited by 511
Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis
Yang, G., Seok, J. K., Kang, H. C., Cho, Y.-Y., Lee, H. S., & Lee, J. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082867 · Cited by 442
Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?
Guttman-Yassky, E., & Krueger, J. G. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.08.008 · Cited by 412
Self-citationJAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
Simpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18898 · Cited by 396
Self-citationSignificance of Skin Barrier Dysfunction in Atopic Dermatitis
Kim, B. E., & Leung, D. Y. M. (2018) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2018.10.3.207 · Cited by 393
Self-citationGuttman-Yassky, E., Thaçi, D., Pangan, A. L., Hong, H. C.-H., Papp, K. A., Reich, K., Beck, L. A., Mohamed, M.-E. F., Othman, A. A., Anderson, J. K., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.025 · Cited by 369
Self-citationKaufman, B. P., Guttman‐Yassky, E., & Alexis, A. F. (2018) · Experimental Dermatology · doi:10.1111/exd.13514 · Cited by 359
Self-citationGuttman-Yassky, E., Blauvelt, A., Eichenfield, L. F., Paller, A. S., Armstrong, A. W., Drew, J., Gopalan, R., & Simpson, E. L. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0079 · Cited by 341
Self-citationTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C.-Y., Liu, Z., Gontijo Lima, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206714 · Cited by 345
Self-citationDupilumab: A review of its use in the treatment of atopic dermatitis
Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.022 · Cited by 343
Ruiz de Morales, J. M. G., Puig, L., Daudén, E., Cañete, J. D., Pablos, J. L., Martín, A. O., Juanatey, C. G., Adán, A., Montalbán, X., Borruel, N., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102429 · Cited by 338
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
Guttman-Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A., Prescilla, R., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.018 · Cited by 317
Self-citationAtopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L., Guttman-Yassky, E., Ong, P. Y., Silverberg, J., & Farrar, J. R. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 305
Self-citationLipid abnormalities in atopic skin are driven by type 2 cytokines
Berdyshev, E., Goleva, E., Bronova, I., Dyjack, N., Rios, C., Jung, J., Taylor, P., Jeong, M., Hall, C. F., Richers, B. N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98006 · Cited by 283
“Discussion AD is an immune system–driven disease associated with skin barrier defects (2).”
BackgroundSelf-citationRacial differences in atopic dermatitis
Brunner, P. M., & Guttman-Yassky, E. (2019) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2018.11.015 · Cited by 282
Self-citationBrunner, P. M., Israel, A., Zhang, N., Leonard, A., Wen, H.-C., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.040 · Cited by 256
Self-citationEpithelial barrier repair and prevention of allergy
Goleva, E., Berdyshev, E., & Leung, D. Y. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124608 · Cited by 251
Self-citationT cells and the skin: from protective immunity to inflammatory skin disorders
Ho, A. W., & Kupper, T. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0162-3 · Cited by 241
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Kim, B. S., Howell, M. D., Sun, K., Papp, K., Nasir, A., & Kuligowski, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.042 · Cited by 226
Guttman-Yassky, E., Pavel, A. B., Zhou, L., Estrada, Y. D., Zhang, N., Xu, H., Peng, X., Wen, H.-C., Govas, P., Gudi, G., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.053 · Cited by 220
Self-citationMontero-Vilchez, T., Segura-Fernández-Nogueras, M.-V., Pérez-Rodríguez, I., Soler-Gongora, M., Martinez-Lopez, A., Fernández-González, A., Molina-Leyva, A., & Arias-Santiago, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020359 · Cited by 206
Therapeutic pipeline for atopic dermatitis: End of the drought?
Paller, A. S., Kabashima, K., & Bieber, T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.006 · Cited by 192
Bieber, T., Thyssen, J. P., Reich, K., Simpson, E. L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16948 · Cited by 152
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
Simpson, E. L., Imafuku, S., Poulin, Y., Ungar, B., Zhou, L., Malik, K., Wen, H.-C., Xu, H., Estrada, Y. D., Peng, X., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.043 · Cited by 120
Self-citationLee, Y., Choi, H. K., N’deh, K. P. U., Choi, Y.-J., Fan, M., Kim, E.-K., Chung, K.-H., & An, J. H. (2020) · Nutrients · doi:10.3390/nu12020411 · Cited by 115
“AD patients compared to that in patients affected by several inhaled allergens, and the increase of secreted Th2 helper cytokines is highly correlated with the disease [2,5,6].”
ResultWang, C., Kraus, C. N., Patel, K. G., Ganesan, A. K., & Grando, S. A. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14573 · Cited by 78
Nakagawa, H., Iizuka, H., Nemoto, O., Shimabe, M., Furukawa, Y., Kikuta, N., & Ootaki, K. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2020.06.005 · Cited by 66
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54559-6 · Cited by 57
Martínez, B. A., Shrotri, S., Kingsmore, K. M., Bachali, P., Grammer, A. C., & Lipsky, P. E. (2022) · Science Advances · doi:10.1126/sciadv.abn4776 · Cited by 56
“For example, T H 17 cells and IL-17 are targets of successful therapeutic intervention in PSO ( 25 , 26 ); in addition, the T H 2 T cell subset is implicated in AD pathogenesis ( 20 ).”
Beck, L. A., Bieber, T., Weidinger, S., Tauber, M., Saeki, H., Irvine, A. D., Eichenfield, L. F., Werfel, T., Arlert, P., Jiang, L., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.11.047 · Cited by 56
Efficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46
Self-citationAbdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45
Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum
Bin, L., Malley, C., Taylor, P., Preethi Boorgula, M., Chavan, S., Daya, M., Mathias, M., Shankar, G., Rafaels, N., Vergara, C., et al. (2021) · Allergy · doi:10.1111/all.14762 · Cited by 33
Self-citationPiscitelli, S. C., Pavel, A. B., McHale, K., Jett, J. E., Collins, J., Gillmor, D., Tabolt, G., Li, R., Song, T., Zhang, N., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.031 · Cited by 30
Self-citationClayton, K., Vallejo, A., Sirvent, S., Davies, J., Porter, G., Reading, I. C., Lim, F., Ardern‐Jones, M. R., & Polak, M. E. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19431 · Cited by 28
Florian, P., Flechsenhar, K. R., Bartnik, E., Ding‐Pfennigdorff, D., Herrmann, M., Bryce, P. J., & Nestle, F. O. (2020) · Experimental Dermatology · doi:10.1111/exd.13942 · Cited by 20
Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials
Agnihotri, G., & Lio, P. A. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00905-7 · Cited by 15
Metadata
- Authors
- Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 139
- Issue
- 4
- Pages
- S65-S76
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2604389567
- Cited by
- 642
- References
- 175
- FWCI
- 51.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.